Literature DB >> 21983037

Multiple stress signals activate mutant p53 in vivo.

Young-Ah Suh1, Sean M Post, Ana C Elizondo-Fraire, Daniela R Maccio, James G Jackson, Adel K El-Naggar, Carolyn Van Pelt, Tamara Terzian, Guillermina Lozano.   

Abstract

p53 levels are tightly regulated in normal cells, and thus, the wild-type p53 protein is nearly undetectable until stimulated through a variety of stresses. In response to stress, p53 is released from its negative regulators, mainly murine double minute 2 (Mdm2), allowing p53 to be stabilized to activate cell-cycle arrest, senescence, and apoptosis programs. Many of the upstream signals that regulate wild-type p53 are known; however, limited information for the regulation of mutant p53 exists. Previously, we showed that wild-type and mutant p53R172H are regulated in a similar manner in the absence of Mdm2 or p16. In addition, this stabilization of mutant p53 is responsible for the gain-of-function metastatic phenotype observed in the mouse. In this report, we examined the role of oncogenes, DNA damage, and reactive oxygen species, signals that stabilize wild-type p53, on the stabilization of mutant p53 in vivo and the consequences of this expression on tumor formation and survival. These factors stabilized mutant p53 protein which oftentimes contributed to exacerbated tumor phenotypes. These findings, coupled with the fact that patients carry p53 mutations without stabilization of p53, suggest that personalized therapeutic schemes may be needed for individual patients depending on their p53 status.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21983037      PMCID: PMC3320147          DOI: 10.1158/0008-5472.CAN-11-0459

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

1.  A high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development.

Authors:  Sean M Post; Alfonso Quintás-Cardama; Vinod Pant; Tomoo Iwakuma; Amir Hamir; James G Jackson; Daniela R Maccio; Gareth L Bond; David G Johnson; Arnold J Levine; Guillermina Lozano
Journal:  Cancer Cell       Date:  2010-09-14       Impact factor: 31.743

Review 2.  Activation of p53 by specific agents in potential cancer therapy.

Authors:  John W Ho; Jing Zheng Song; Yuet Kin Leung
Journal:  Curr Med Chem Anticancer Agents       Date:  2005-03

Review 3.  p53 mutation heterogeneity in cancer.

Authors:  T Soussi; G Lozano
Journal:  Biochem Biophys Res Commun       Date:  2005-06-10       Impact factor: 3.575

4.  Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome.

Authors:  Kenneth P Olive; David A Tuveson; Zachary C Ruhe; Bob Yin; Nicholas A Willis; Roderick T Bronson; Denise Crowley; Tyler Jacks
Journal:  Cell       Date:  2004-12-17       Impact factor: 41.582

5.  Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.

Authors:  Gene A Lang; Tomoo Iwakuma; Young-Ah Suh; Geng Liu; V Ashutosh Rao; John M Parant; Yasmine A Valentin-Vega; Tamara Terzian; Lisa C Caldwell; Louise C Strong; Adel K El-Naggar; Guillermina Lozano
Journal:  Cell       Date:  2004-12-17       Impact factor: 41.582

6.  ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor.

Authors:  Delin Chen; Ning Kon; Muyang Li; Wenzhu Zhang; Jun Qin; Wei Gu
Journal:  Cell       Date:  2005-07-01       Impact factor: 41.582

7.  The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.

Authors:  F J Stott; S Bates; M C James; B B McConnell; M Starborg; S Brookes; I Palmero; K Ryan; E Hara; K H Vousden; G Peters
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

8.  E1A signaling to p53 involves the p19(ARF) tumor suppressor.

Authors:  E de Stanchina; M E McCurrach; F Zindy; S Y Shieh; G Ferbeyre; A V Samuelson; C Prives; M F Roussel; C J Sherr; S W Lowe
Journal:  Genes Dev       Date:  1998-08-01       Impact factor: 11.361

9.  Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2.

Authors:  T Kamijo; J D Weber; G Zambetti; F Zindy; M F Roussel; C J Sherr
Journal:  Proc Natl Acad Sci U S A       Date:  1998-07-07       Impact factor: 11.205

10.  Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6.

Authors:  D A Freedman; A J Levine
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

View more
  57 in total

1.  Impact of the Mdm2(SNP309-G) allele on a murine model of colorectal cancer.

Authors:  X Zhang; L Pageon; S M Post
Journal:  Oncogene       Date:  2014-12-01       Impact factor: 9.867

Review 2.  The Mdm network and its regulation of p53 activities: a rheostat of cancer risk.

Authors:  Christine M Eischen; Guillermina Lozano
Journal:  Hum Mutat       Date:  2014-03-06       Impact factor: 4.878

3.  Constitutive Activation of DNA Damage Checkpoint Signaling Contributes to Mutant p53 Accumulation via Modulation of p53 Ubiquitination.

Authors:  Rebecca A Frum; Ian M Love; Priyadarshan K Damle; Nitai D Mukhopadhyay; Swati Palit Deb; Sumitra Deb; Steven R Grossman
Journal:  Mol Cancer Res       Date:  2016-03-10       Impact factor: 5.852

Review 4.  Mutant p53: one name, many proteins.

Authors:  William A Freed-Pastor; Carol Prives
Journal:  Genes Dev       Date:  2012-06-15       Impact factor: 11.361

5.  Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4.

Authors:  Alla Polotskaia; Gu Xiao; Katherine Reynoso; Che Martin; Wei-Gang Qiu; Ronald C Hendrickson; Jill Bargonetti
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-02       Impact factor: 11.205

6.  p16(INK4a) protects against dysfunctional telomere-induced ATR-dependent DNA damage responses.

Authors:  Yang Wang; Norman Sharpless; Sandy Chang
Journal:  J Clin Invest       Date:  2013-09-16       Impact factor: 14.808

7.  Mutant p53 Sequestration of the MDM2 Acidic Domain Inhibits E3 Ligase Activity.

Authors:  Leixiang Yang; Tanjing Song; Qian Cheng; Lihong Chen; Jiandong Chen
Journal:  Mol Cell Biol       Date:  2019-02-04       Impact factor: 4.272

8.  Lack of Immunomodulatory Interleukin-27 Enhances Oncogenic Properties of Mutant p53 In Vivo.

Authors:  Denada Dibra; Abhisek Mitra; Melisa Newman; Xueqing Xia; Jeffry J Cutrera; Mihai Gagea; Eugenie S Kleinerman; Guillermina Lozano; Shulin Li
Journal:  Clin Cancer Res       Date:  2016-03-15       Impact factor: 12.531

9.  Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer.

Authors:  Tomer Cooks; Ioannis S Pateras; Ohad Tarcic; Hilla Solomon; Aaron J Schetter; Sylvia Wilder; Guillermina Lozano; Eli Pikarsky; Tim Forshew; Nitzan Rosenfeld; Nitzan Rozenfeld; Noam Harpaz; Steven Itzkowitz; Curtis C Harris; Varda Rotter; Vassilis G Gorgoulis; Moshe Oren
Journal:  Cancer Cell       Date:  2013-05-13       Impact factor: 31.743

10.  MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program.

Authors:  Zijun Y Xu-Monette; Michael B Møller; Alexander Tzankov; Santiago Montes-Moreno; Wenwei Hu; Ganiraju C Manyam; Louise Kristensen; Lei Fan; Carlo Visco; Karen Dybkaer; April Chiu; Wayne Tam; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Qin Huang; Jooryung Huh; Weiyun Ai; Maurilio Ponzoni; Andrés J M Ferreri; Lin Wu; Xiaoying Zhao; Carlos E Bueso-Ramos; Sa A Wang; Ronald S Go; Yong Li; Jane N Winter; Miguel A Piris; L Jeffrey Medeiros; Ken H Young
Journal:  Blood       Date:  2013-08-27       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.